- Veterinary antihistamines, used to treat allergic reactions, inflammation, and itching in animals, are increasingly critical in veterinary medicine due to the rising prevalence of allergic conditions among pets and livestock. Their role in improving animal comfort and quality of life positions them as essential components of modern veterinary care
- The escalating demand for veterinary antihistamines is primarily driven by increasing pet ownership, heightened awareness of pet health, and advancements in veterinary diagnostics that lead to timely identification and treatment of allergies
- North America dominated the veterinary antihistamines market with the largest revenue share of 38.13% in 2024, supported by a well-established veterinary healthcare infrastructure, growing expenditure on companion animal care, and a strong presence of key pharmaceutical companies. The U.S. saw notable growth due to high rates of pet insurance and proactive allergy management by pet owners
- Asia-Pacific is expected to be the fastest growing region in the veterinary antihistamines market during the forecast period, projected at a CAGR of 10.4%, fueled by increasing urbanization, a growing pet population, and rising disposable incomes in countries such as China, India, and South Kore
- The H1-receptor antagonists segment dominated the veterinary antihistamines market with a market share of 58.4% in 2024, owing to their widespread usage in treating allergic conditions such as atopic dermatitis, pruritus, and insect bites in companion animals. These drugs, including diphenhydramine, cetirizine, and loratadine, are often considered first-line therapies for managing acute allergic responses in pets
